Personalis (PSNL) Competitors $3.08 -0.23 (-6.82%) As of 12:30 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PSNL vs. VRDN, GRAL, AVAH, CDNA, FTRE, PNTG, CSTL, FLGT, AUNA, and TALKShould you be buying Personalis stock or one of its competitors? The main competitors of Personalis include Viridian Therapeutics (VRDN), Grail (GRAL), Aveanna Healthcare (AVAH), CareDx (CDNA), Fortrea (FTRE), The Pennant Group (PNTG), Castle Biosciences (CSTL), Fulgent Genetics (FLGT), Auna (AUNA), and Talkspace (TALK). These companies are all part of the "healthcare" industry. Personalis vs. Viridian Therapeutics Grail Aveanna Healthcare CareDx Fortrea The Pennant Group Castle Biosciences Fulgent Genetics Auna Talkspace Personalis (NASDAQ:PSNL) and Viridian Therapeutics (NASDAQ:VRDN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, community ranking, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk. Is PSNL or VRDN more profitable? Personalis has a net margin of -104.52% compared to Viridian Therapeutics' net margin of -85,127.16%. Personalis' return on equity of -66.07% beat Viridian Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Personalis-104.52% -66.07% -41.34% Viridian Therapeutics -85,127.16%-70.12%-41.49% Does the MarketBeat Community favor PSNL or VRDN? Personalis received 50 more outperform votes than Viridian Therapeutics when rated by MarketBeat users. However, 78.72% of users gave Viridian Therapeutics an outperform vote while only 68.13% of users gave Personalis an outperform vote. CompanyUnderperformOutperformPersonalisOutperform Votes12468.13% Underperform Votes5831.87% Viridian TherapeuticsOutperform Votes7478.72% Underperform Votes2021.28% Do institutionals and insiders hold more shares of PSNL or VRDN? 61.9% of Personalis shares are held by institutional investors. 4.1% of Personalis shares are held by insiders. Comparatively, 0.7% of Viridian Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more risk and volatility, PSNL or VRDN? Personalis has a beta of 1.89, indicating that its share price is 89% more volatile than the S&P 500. Comparatively, Viridian Therapeutics has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500. Do analysts rate PSNL or VRDN? Personalis presently has a consensus price target of $7.80, indicating a potential upside of 136.36%. Viridian Therapeutics has a consensus price target of $35.70, indicating a potential upside of 182.21%. Given Viridian Therapeutics' higher possible upside, analysts plainly believe Viridian Therapeutics is more favorable than Personalis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Personalis 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Viridian Therapeutics 0 Sell rating(s) 3 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.75 Which has stronger valuation and earnings, PSNL or VRDN? Personalis has higher revenue and earnings than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than Personalis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPersonalis$84.61M3.44-$108.30M-$1.37-2.41Viridian Therapeutics$302K3,413.20-$237.73M-$3.77-3.36 Does the media prefer PSNL or VRDN? In the previous week, Viridian Therapeutics had 2 more articles in the media than Personalis. MarketBeat recorded 3 mentions for Viridian Therapeutics and 1 mentions for Personalis. Viridian Therapeutics' average media sentiment score of 1.77 beat Personalis' score of 1.76 indicating that Viridian Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Personalis 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Viridian Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SummaryPersonalis beats Viridian Therapeutics on 12 of the 18 factors compared between the two stocks. Remove Ads Get Personalis News Delivered to You Automatically Sign up to receive the latest news and ratings for PSNL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PSNL vs. The Competition Export to ExcelMetricPersonalisMedical laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$291.27M$2.80B$5.53B$7.50BDividend YieldN/A24.77%4.87%4.05%P/E Ratio-1.9612.9623.1618.08Price / Sales3.44179.56356.5786.83Price / CashN/A57.5638.1634.64Price / Book1.254.176.483.99Net Income-$108.30M-$22.21M$3.21B$247.18M7 Day Performance-8.84%-3.36%-4.96%-4.25%1 Month Performance-19.71%3.40%-0.13%-6.87%1 Year Performance135.71%-2.32%6.26%-3.73% Personalis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PSNLPersonalis4.1264 of 5 stars$3.08-6.8%$7.80+153.7%+144.4%$271.59M$84.61M-1.83400Positive NewsGap DownVRDNViridian Therapeutics1.188 of 5 stars$15.46+1.3%$35.70+130.9%-22.2%$1.26B$302,000.00-3.5950Positive NewsGap DownGRALGrail0.6576 of 5 stars$32.13+6.1%$20.00-37.8%N/A$1.09B$125.60M0.001,360Positive NewsGap DownAVAHAveanna Healthcare0.6966 of 5 stars$5.58+5.5%$4.94-11.5%+112.8%$1.09B$2.02B-16.4133,500News CoverageGap DownCDNACareDx3.1749 of 5 stars$19.61+1.5%$31.83+62.3%+73.0%$1.09B$333.79M-7.26740Positive NewsGap UpFTREFortrea2.3053 of 5 stars$9.40+7.2%$19.00+102.1%-82.4%$847.88M$2.70B-2.7518,000Gap DownHigh Trading VolumePNTGThe Pennant Group3.2794 of 5 stars$24.29+3.8%$34.80+43.3%+25.8%$836.31M$695.24M35.725,340Analyst ForecastGap DownCSTLCastle Biosciences2.0452 of 5 stars$20.98+2.2%$40.00+90.7%-10.9%$587.59M$332.07M104.91540FLGTFulgent Genetics2.7264 of 5 stars$16.96-0.8%$16.00-5.7%-19.6%$522.86M$283.47M-3.071,010Short Interest ↑Gap DownHigh Trading VolumeAUNAAuna4.0563 of 5 stars$7.06+0.4%$13.53+91.6%-24.9%$521.86M$4.39B18.5814,958TALKTalkspace4.0306 of 5 stars$2.87+2.5%$4.38+52.4%-26.6%$483.41M$187.59M287.29500Analyst ForecastShort Interest ↓News CoverageGap Down Remove Ads Related Companies and Tools Related Companies VRDN Competitors GRAL Competitors AVAH Competitors CDNA Competitors FTRE Competitors PNTG Competitors CSTL Competitors FLGT Competitors AUNA Competitors TALK Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PSNL) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredNearly $3 Trillion Gone…Nearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredHow you could profit from Elon’s latest AI breakthroughEvery single one of Elon's projects minted an entire new class of millionaires. And xAI could be next in li...Behind the Markets | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredTrump’s betrayal exposed Fair warning: this will not make for easy viewing. Especially if you voted for Trump, put your faith in hi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Personalis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Personalis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PSNL Stock Free PSNL Stock Alerts